The Halland Osteoarthritis Cohort

Osteoarthritis, Knee Clinical Trial

— HALLOA  

Official title:

The Halland Osteoarthritis (HALLOA) Cohort Study - a Five-year Observational Longitudinal Study With Focus on Metabolic Osteoarthritis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04928170
• Other study ID #: HALLOA
• Status: Active, not recruiting
• Start date: November 1, 2016
• Est. completion date: October 1, 2024

Study information

• Verified date: May 2021
• Source: FoU Center Spenshult
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Osteoarthritis is the most common musculoskeletal disease and is characterized by cartilage destruction, osteophyte formation, subchondral bone sclerosis and cysts. Modern treatment strategies, as well as preventive measures, include early detection and knowledge of the early course of the disease. This includes how stress patterns, physical activity, impaired function and metabolic changes and other comorbidities affect development and possible associations with osteoarthritis.

The overall objective was to study the early development of osteoarthritis of the knee and its association with hand- and general osteoarthritis, metabolic diseases, biomarkers, long-term pain, physical function and stress patterns

Description:

The overall objective was to study the early development of osteoarthritis of the knee and its association with hand- and general osteoarthritis, metabolic diseases, biomarkers, long-term pain, physical function and stress patterns.

The project includes 4 different research areas that are studied with the help of several smaller sub-studies:

Research area 1: Metabolic osteoarthritis - to study the connections between metabolic factors and osteoarthritis development in the knee and hand.

A. Relationship between knee osteoarthritis and metabolic factors B. Relationship between osteoarthritis of the hand and metabolic factors Research area 2: Biomarkers in knee and hand osteoarthritis - to study cartilage and bone markers that reflect different processes in osteoarthritis development, e.g. inflammation, matrix degradation both in the short and long term Research area 3: Pain and osteoarthritis - to study pain development and pain pressure thresholds in relation to lifestyle, depression and health-related quality of life in individuals with symptomatic knee osteoarthritis Research area 4: Physical function and osteoarthritis - to study physical function, physical activity and measured stress patterns, as well as changes in stress patterns and the relationship between these and the development of osteoarthritis over time.

Study design This is a longitudinal cohort study including 306 individuals with knee pain in the southwest of Sweden, the Halland osteoarthritis (HALLOA) cohort. The enrolments took place from 2017-2019. The participants were recruited: 1) by primary health care clinics when searching care for knee pain, or 2) by advertisements in local newspapers. The inclusion criterions were current knee pain, aged 30-65 years, with no former known radiographic knee osteoarthritis (RKOA). the exclusion criterions were no cruciate ligament rupture or rheumatologic disorder. A general practitioner examined all participants to confirm the exclusion criteria.

The cohort will be followed for five years with yearly follow-ups.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 312
• Est. completion date: October 1, 2024
• Est. primary completion date: October 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 65 Years

Eligibility

Inclusion Criteria:

Knee pain

Exclusion Criteria:

Cruciate ligament injury and rheumatic disease (RA, PsoA, As, Sponylarthritis etc)

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis Hand
• Osteoarthritis, Knee

Locations

Country	Name	City	State
Sweden	Spenshult Research and Development center (FoU Spenshult)	Halmstad

Sponsors (2)

Lead Sponsor	Collaborator
FoU Center Spenshult	The Swedish Rheumatism Ass

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BMI (kg/m2)	weight (kg) and height (m) are meassured and BMI will be calculated	At baseline
Primary	BMI (kg/m2)	weight (kg) and height (m) are meassured and BMI will be calculated	At 2 years follow-up
Primary	BMI (kg/m2)	weight (kg) and height (m) are meassured and BMI will be calculated	At 5 years follow-up
Primary	Abdominal circumference (cm)	Abdominal circumference are meassured with measuring tape at navel height	At baseline
Primary	Abdominal circumference (cm)	Abdominal circumference are meassured with measuring tape at navel height	At 2 years follow-up
Primary	Abdominal circumference (cm)	Abdominal circumference are meassured with measuring tape at navel height	At 5 years follow-up
Primary	Body composition	Body composition are assessed by Inbody 770, which gives data on proportion of muscle and body fat (separate meassures on visceral fat	At baseline
Primary	Body composition	Body composition are assessed by Inbody 770, which gives data on proportion of muscle and body fat (separate meassures on visceral fat	At 2 years follow-up
Primary	Body composition	Body composition are assessed by Inbody 770, which gives data on proportion of muscle and body fat (separate meassures on visceral fat	At 5 years follow-up
Primary	Glucos	Fasting glucos (mmol/L) meassured in serum	At Baseline
Primary	Glucos	Fasting glucos (mmol/L) meassured in serum	At 1 year follow-up
Primary	Glucos	Fasting glucos (mmol/L) meassured in serum	At 2 years follow-up
Primary	Glucos	Fasting glucos (mmol/L) meassured in serum	At 3 years follow-up
Primary	Glucos	Fasting glucos (mmol/L) meassured in serum	At 4 years follow-up
Primary	Glucos	Fasting glucos (mmol/L) meassured in serum	At 5 years follow-up
Primary	HbA1c	HbA1c (mmol/mol) meassured in serum	At baseline
Primary	HbA1c	HbA1c (mmol/mol) meassured in serum	At 1 year follow-up
Primary	HbA1c	HbA1c (mmol/mol) meassured in serum	At 2 years follow-up
Primary	HbA1c	HbA1c (mmol/mol) meassured in serum	At 3 years follow-up
Primary	HbA1c	HbA1c (mmol/mol) meassured in serum	At 4 years follow-up
Primary	HbA1c	HbA1c (mmol/mol) meassured in serum	At 5 years follow-up
Primary	Total-cholesterol	Total-cholesterol (mmol/L) meassured in serum	At baseline
Primary	Total-cholesterol	Total-cholesterol (mmol/L) meassured in serum	At 1 year follow-up
Primary	Total-cholesterol	Total-cholesterol (mmol/L) meassured in serum	At 2 years follow-up
Primary	Total-cholesterol	Total-cholesterol (mmol/L) meassured in serum	At 3 years follow-up
Primary	Total-cholesterol	Total-cholesterol (mmol/L) meassured in serum	At 4 years follow-up
Primary	Total-cholesterol	Total-cholesterol (mmol/L) meassured in serum	At 5 years follow-up
Primary	Triglycerides	Triglycerides (mmol/L) meassured in serum	At baseline
Primary	Triglycerides	Triglycerides (mmol/L) meassured in serum	At 1 year follow-up
Primary	Triglycerides	Triglycerides (mmol/L) meassured in serum	At 2 years follow-up
Primary	Triglycerides	Triglycerides (mmol/L) meassured in serum	At 3 years follow-up
Primary	Triglycerides	Triglycerides (mmol/L) meassured in serum	At 4 years follow-up
Primary	Triglycerides	Triglycerides (mmol/L) meassured in serum	At 5 years follow-up
Primary	LDL-cholesterol	LDL-cholesterol (mmol/L) meassured in serum	At baseline
Primary	LDL-cholesterol	LDL-cholesterol (mmol/L) meassured in serum	At 1 year follow-up
Primary	LDL-cholesterol	LDL-cholesterol (mmol/L) meassured in serum	At 2 years follow-up
Primary	LDL-cholesterol	LDL-cholesterol (mmol/L) meassured in serum	At 3 years follow-up
Primary	LDL-cholesterol	LDL-cholesterol (mmol/L) meassured in serum	At 4 years follow-up
Primary	LDL-cholesterol	LDL-cholesterol (mmol/L) meassured in serum	At 5 years follow-up
Primary	HDL-cholesterol	HDL-cholesterol (mmol/L) meassured in serum	At baseline
Primary	HDL-cholesterol	HDL-cholesterol (mmol/L) meassured in serum	At 1 year follow-up
Primary	HDL-cholesterol	HDL-cholesterol (mmol/L) meassured in serum	At 2 years follow-up
Primary	HDL-cholesterol	HDL-cholesterol (mmol/L) meassured in serum	At 3 years follow-up
Primary	HDL-cholesterol	HDL-cholesterol (mmol/L) meassured in serum	At 4 years follow-up
Primary	HDL-cholesterol	HDL-cholesterol (mmol/L) meassured in serum	At 5 years follow-up
Primary	Sensitive C-Reactive Protein (CRP)	sensitive CRP (g/L) meassured in serum	At baseline
Primary	Sensitive C-Reactive Protein (CRP)	sensitive CRP (g/L) meassured in serum	At 1 year follow-up
Primary	Sensitive C-Reactive Protein (CRP)	sensitive CRP (g/L) meassured in serum	At 2 years follow-up
Primary	Sensitive C-Reactive Protein (CRP)	sensitive CRP (g/L) meassured in serum	At 3 years follow-up
Primary	Sensitive C-Reactive Protein (CRP)	sensitive CRP (g/L) meassured in serum	At 4 years follow-up
Primary	Sensitive C-Reactive Protein (CRP)	sensitive CRP (g/L) meassured in serum	At 5 years follow-up
Primary	Interleukin-1 (IL-1)	IL-1 (pg/mL) meassured in plasma with ELISA	At baseline
Primary	Interleukin-1 (IL-1)	IL-1 (pg/mL) meassured in plasma with ELISA	At 1 year follow-up
Primary	Interleukin-1 (IL-1)	IL-1 (pg/mL) meassured in plasma with ELISA	At 2 years follow-up
Primary	Interleukin-1 (IL-1)	IL-1 (pg/mL) meassured in plasma with ELISA	At 3 years follow-up
Primary	Interleukin-1 (IL-1)	IL-1 (pg/mL) meassured in plasma with ELISA	At 4 years follow-up
Primary	Interleukin-1 (IL-1)	IL-1 (pg/mL) meassured in plasma with ELISA	At 5 years follow-up
Primary	Interleukin-6 (IL-6)	IL-6 (pg/mL) meassured in plasma with ELISA	At baseline
Primary	Interleukin-6 (IL-6)	IL-6 (pg/mL) meassured in plasma with ELISA	At 1 year follow-up
Primary	Interleukin-6 (IL-6)	IL-6 (pg/mL) meassured in plasma with ELISA	At 2 years follow-up
Primary	Interleukin-6 (IL-6)	IL-6 (pg/mL) meassured in plasma with ELISA	At 3 years follow-up
Primary	Interleukin-6 (IL-6)	IL-6 (pg/mL) meassured in plasma with ELISA	At 4 years follow-up
Primary	Interleukin-6 (IL-6)	IL-6 (pg/mL) meassured in plasma with ELISA	At 5 years follow-up
Primary	Tumor Necrosis Factor-alfa (TNF-alfa)	TNF-alfa (pg/mL) meassured in plasma with ELISA	At baseline
Primary	Tumor Necrosis Factor-alfa (TNF-alfa)	TNF-alfa (pg/mL) meassured in plasma with ELISA	At 1 year follow-up
Primary	Tumor Necrosis Factor-alfa (TNF-alfa)	TNF-alfa (pg/mL) meassured in plasma with ELISA	At 2 years follow-up
Primary	Tumor Necrosis Factor-alfa (TNF-alfa)	TNF-alfa (pg/mL) meassured in plasma with ELISA	At 3 years folllow-up
Primary	Tumor Necrosis Factor-alfa (TNF-alfa)	TNF-alfa (pg/mL) meassured in plasma with ELISA	At 4 years follow-up
Primary	Tumor Necrosis Factor-alfa (TNF-alfa)	TNF-alfa (pg/mL) meassured in plasma with ELISA	At 5 years follow-up
Primary	Leptin	Leptin (ng/mL) meassured in serum with ELISA	At baseline
Primary	Leptin	Leptin (ng/mL) meassured in serum with ELISA	At 1 year follow-up
Primary	Leptin	Leptin (ng/mL) meassured in serum with ELISA	At 2 years follow-up
Primary	Leptin	Leptin (ng/mL) meassured in serum with ELISA	At 3 years follow-up
Primary	Leptin	Leptin (ng/mL) meassured in serum with ELISA	At 4 years follow-up
Primary	Leptin	Leptin (ng/mL) meassured in serum with ELISA	At 5 years follow-up
Primary	Galectin-1	Galectin-1 (ng/mL) meassured in plasma with ELISA	At baseline
Primary	Galectin-1	Galectin-1 (ng/mL) meassured in plasma with ELISA	At 1 year follow-up
Primary	Galectin-1	Galectin-1 (ng/mL) meassured in plasma with ELISA	At 2 years follow-up
Primary	Galectin-1	Galectin-1 (ng/mL) meassured in plasma with ELISA	At 3 years follow-up
Primary	Galectin-1	Galectin-1 (ng/mL) meassured in plasma with ELISA	At 4 years follow-up
Primary	Galectin-1	Galectin-1 (ng/mL) meassured in plasma with ELISA	At 5 years follow-up
Primary	One-leg rise	Knee strenght are assessed by one-leg rise	At baseline
Primary	One-leg rise	Knee strenght are assessed by one-leg rise	At 2 years follow-up
Primary	One-leg rise	Knee strenght are assessed by one-leg rise	At 5 years follow-up
Primary	30s-chair stand test	Knee strenght are assessed by 30s-chair stand test	At baseline
Primary	30s-chair stand test	Knee strenght are assessed by 30s-chair stand test	At 2 years follow-up
Primary	30s-chair stand test	Knee strenght are assessed by 30s-chair stand test	At 5 years follow-up
Primary	Maximal voluntary isometric contraction of Quadriceps	Maximal voluntary isometric contraction of Quadriceps assessed by dynamometer (N)	At baseline
Primary	Maximal voluntary isometric contraction of Quadriceps	Maximal voluntary isometric contraction of Quadriceps assessed by dynamometer (N)	At 2 years follow-up
Primary	Maximal voluntary isometric contraction of Quadriceps	Maximal voluntary isometric contraction of Quadriceps assessed by dynamometer (N)	At 5 years follow-up
Primary	Hand strenght	Hand strenght are assessed by grippit (N)	At baseline
Primary	Hand strenght	Hand strenght are assessed by grippit (N)	At 2 years follow-up
Primary	Hand strenght	Hand strenght are assessed by grippit (N)	At 5 years follow-up
Primary	Fitness	Fitness are assessed by Åstrands test	At 2 years follow-up
Primary	Fitness	Fitness are assessed by Åstrands test	At 5 years follow-up
Primary	Pain thresholds	pain threshold are assesed by computerized pressure algometry on eight predefined tender points out of the 18 points as part of the definition of fibromyalgia	At baseline
Primary	Pain thresholds	pain threshold are assesed by computerized pressure algometry on eight predefined tender points out of the 18 points as part of the definition of fibromyalgia	At 2 years follow-up
Primary	Pain thresholds	pain threshold are assesed by computerized pressure algometry on eight predefined tender points out of the 18 points as part of the definition of fibromyalgia	At 5 years follow-up
Primary	Knee injury and osteoarthritis outcome score (KOOS)	KOOS consists of 5 subscales, assessing self reported knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).	At baseline
Primary	Knee injury and osteoarthritis outcome score (KOOS)	KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).	At 1 year follow-up
Primary	Knee injury and osteoarthritis outcome score (KOOS)	KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).	At 2 years follow-up
Primary	Knee injury and osteoarthritis outcome score (KOOS)	KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).	At 3 years follow-up
Primary	Knee injury and osteoarthritis outcome score (KOOS)	KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).	At 4 years follow-up
Primary	Knee injury and osteoarthritis outcome score (KOOS)	KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).	At 5 years follow-up
Primary	Pain mannequin	Patient reported pain distribution	At baseline
Primary	Pain mannequin	Patient reported pain distribution	At 1 year follow-up
Primary	Pain mannequin	Patient reported pain distribution	At 2 years follow-up
Primary	Pain mannequin	Patient reported pain distribution	At 3 years follow-up
Primary	Pain mannequin	Patient reported pain distribution	At 4 years follow-up
Primary	Pain mannequin	Patient reported pain distribution	At 5 years follow-up
Primary	Pain intensity	Patient reported pain intensity by NRS scale 0-10 (best to worst)	At baseline
Primary	Pain intensity	Patient reported pain intensity by NRS scale 0-10 (best to worst)	At 1 year follow-up
Primary	Pain intensity	Patient reported pain intensity by NRS scale 0-10 (best to worst)	At 2 years follow-up
Primary	Pain intensity	Patient reported pain intensity by NRS scale 0-10 (best to worst)	At 3 years follow-up
Primary	Pain intensity	Patient reported pain intensity by NRS scale 0-10 (best to worst)	At 4 years follow-up
Primary	Patient intensity	Patient reported pain intensity by NRS scale 0-10 (best to worst)	At 5 years follow-up
Primary	Radiographic assessment of the knees	radiographic assessment of tibiofemoral- and patellofemoral joint in the knee	At baseline
Primary	Radiographic assessment of the knees	radiographic assessment of tibiofemoral- and patellofemoral joint in the knee	At 1 year follow-up
Primary	Radiographic assessment of the knees	radiographic assessment of tibiofemoral- and patellofemoral joint in the knee	At 2 years follow-up
Primary	Radiographic assessment of the knees	radiographic assessment of tibiofemoral- and patellofemoral joint in the knee	At 3 years follow-up
Primary	Radiographic assessment of the knees	radiographic assessment of tibiofemoral- and patellofemoral joint in the knee	At 4 years follow-up
Primary	Radiographic assessment of the knees	radiographic assessment of tibiofemoral- and patellofemoral joint in the knee	At 5 years follow-up
Primary	Radiographic assessment of the hands	Radiographic assessment of the hands.	At 2 years follow-up
Primary	Radiographic assessment of the hands	Radiographic assessment of the hands.	At 5 years follow-up
Primary	Mechanical load	Movement behavior measured with a triaxle accelerometer at work and leisure over 7 days	At inclusion
Primary	Mechanical load	Movement behavior measured with a triaxle accelerometer at work and leisure over 7 days	At 2 years follow-up
Primary	Mechanical load	Movement behavior measured with a triaxle accelerometer at work and leisure over 7 days	At 5 years follow-up
Secondary	Blood samples for biobanking	serum and plasma for biobanking in -70 degrees celcius	At baseline
Secondary	Blood samples for biobanking	serum and plasma for biobanking in -70 degrees celcius	At 1 year follow-up
Secondary	Blood samples for biobanking	serum and plasma for biobanking in -70 degrees celcius	At 2 years follow-up
Secondary	Blood samples for biobanking	serum and plasma for biobanking in -70 degrees celcius	At 3 years follow-up
Secondary	Blood samples for biobanking	serum and plasma for biobanking in -70 degrees celcius	At 4 years follow-up
Secondary	Blood samples for biobanking	serum and plasma for biobanking in -70 degrees celcius	At 5 years follow-up
Secondary	Patient reported physical activity	Patient reported physical activity with questions duration and intensity according to WHO recommendations	At baseline
Secondary	Patient reported physical activity	Patient reported physical activity with questions duration and intensity according to WHO recommendations	At 1 year follow-up
Secondary	Patient reported physical activity	Patient reported physical activity with questions duration and intensity according to WHO recommendations	At 2 years follow-up
Secondary	Patient reported physical activity	Patient reported physical activity with questions duration and intensity according to WHO recommendations	At 3 years follow-up
Secondary	Patient reported physical activity	Patient reported physical activity with questions duration and intensity according to WHO recommendations	At 4 years follow-up
Secondary	Patient reported physical activity	Patient reported physical activity with questions duration and intensity according to WHO recommendations	At 5 years follow-up
Secondary	Patient reported smoking and snuff habits	Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff	At baseline
Secondary	Patient reported smoking and snuff habits	Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff	At 1 years follow-up
Secondary	Patient reported smoking and snuff habits	Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff	At 2 years follow-up
Secondary	Patient reported smoking and snuff habits	Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff	At 3 years follow-up
Secondary	Patient reported smoking and snuff habits	Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff	At 4 years follow-up
Secondary	Patient reported smoking and snuff habits	Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff	At 5 years follow-up
Secondary	Patient reported diets	Patient reported diets and intake of fruits and sweets	At baseline
Secondary	Patient reported diets	Patient reported diets and intake of fruits and sweets	At 1 year follow-up
Secondary	Patient reported diets	Patient reported diets and intake of fruits and sweets	At 2 years follow-up
Secondary	Patient reported diets	Patient reported diets and intake of fruits and sweets	At 3 years follow-up
Secondary	Patient reported diets	Patient reported diets and intake of fruits and sweets	At 4 years follow-up
Secondary	Patient reported diets	Patient reported diets and intake of fruits and sweets	At 5 years follow-up
Secondary	Patient reported alcohol habits	Patient reported alcohol habis assessed by AUDIT C	At baseline
Secondary	Patient reported alcohol habits	Patient reported alcohol habis assessed by AUDIT C	At 1 year follow-up
Secondary	Patient reported alcohol habits	Patient reported alcohol habis assessed by AUDIT C	At 2 years follow-up
Secondary	Patient reported alcohol habits	Patient reported alcohol habis assessed by AUDIT C	At 3 years follow-up
Secondary	Patient reported alcohol habits	Patient reported alcohol habis assessed by AUDIT C	At 4 years follow-up
Secondary	Patient reported alcohol habits	Patient reported alcohol habis assessed by AUDIT C	At 5 years follow-up
Secondary	Hospital Anxiety and Depression Scale (HADS)	HADS is a simple self-assessment form that shows a measure of the patient's mood.	At baseline
Secondary	Hospital Anxiety and Depression Scale (HADS)	HADS is a simple self-assessment form that shows a measure of the patient's mood.	At 1 year follow-up
Secondary	Hospital Anxiety and Depression Scale (HADS)	HADS is a simple self-assessment form that shows a measure of the patient's mood.	At 2 years follow-up
Secondary	Hospital Anxiety and Depression Scale (HADS)	HADS is a simple self-assessment form that shows a measure of the patient's mood.	At 3 years follow-up
Secondary	Hospital Anxiety and Depression Scale (HADS)	HADS is a simple self-assessment form that shows a measure of the patient's mood.	At 4 years follow-up
Secondary	Hospital Anxiety and Depression Scale (HADS)	HADS is a simple self-assessment form that shows a measure of the patient's mood.	At 5 years follow-up
Secondary	Health literacy	Health literacy assessed with the Swedish Functional Health Literacy scale	At 2 years follow-up
Secondary	Health literacy	Health literacy assessed with the Swedish Functional Health Literacy scale	At 3 years follow-up
Secondary	Health literacy	Health literacy assessed with the Swedish Functional Health Literacy scale	At 5 years follow-up
Secondary	Clinical examination of the knees	Clinical examination to assessing clinical knee OA	At baseline
Secondary	Clinical examination of the knees	Clinical examination to assessing clinical knee OA	At 2 years follow-up
Secondary	Clinical examination of the knees	Clinical examination to assessing clinical knee OA	At 5 years follow-up
Secondary	Clinical examination of the hands	Clinical examination of the hands assessing clinical hand OA	At baseline
Secondary	Clinical examination of the hands	Clinical examination of the hands assessing clinical hand OA	At 2 years follow-up
Secondary	Clinical examination of the hands	Clinical examination of the hands assessing clinical hand OA	At 5 years follow-up
Secondary	Blood pressure	Blood pressure assessed in sitting position after rest, mmHg	At baseline
Secondary	Blood pressure	Blood pressure assessed in sitting position after rest, mmHg	At 2 years follow-up
Secondary	Blood pressure	Blood pressure assessed in sitting position after rest, mmHg	At 5 years follow-up